FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to aqueous compositions for anti-IL17a antibodies. An aqueous pharmaceutical composition suitable for parenteral administration to a subject to inhibit the activity of an IL17a protein contains pharmaceutically effective amount of an anti-IL17a antibody containing a VHH-derivative domain and a variable VL domain; a histidine-based buffer agent; and effective amount of sugar-based alcohol as an osmotic agent. Another option of an aqueous pharmaceutical composition, the use of an aqueous pharmaceutical composition for the treatment of an IL17a-mediated disease, a method for the treatment of an IL17a-mediated disease, a method for obtaining an aqueous pharmaceutical composition are also disclosed.
EFFECT: group of inventions provides colloidal stability, thermal stability, reduction of antibody aggregation and homogeneity of antibodies in the composition.
37 cl, 33 dwg, 44 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTIBODY TO PD-1 OF PROLGOLIMAB AND ITS USE | 2019 |
|
RU2806320C2 |
AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND THE USE THEREOF | 2020 |
|
RU2745814C1 |
TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
PHARMACEUTICAL COMPOSITION OF ANTI-CD20 ANTIBODY AND USE THEREOF | 2022 |
|
RU2824627C2 |
METHOD FOR TREATMENT OF MALIGNANT NEOPLASM, USING COMBINATION OF ANTIBODY TO PD-1 AND CHEMOTHERAPEUTIC AGENT | 2021 |
|
RU2787457C2 |
METHODS FOR TREATMENT USING ANTI-IL-17A ANTIBODIES | 2016 |
|
RU2754683C2 |
MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TO CD20 | 2018 |
|
RU2724469C2 |
GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
TREATMENT OF SKIN LESIONS AND ITCHING IN PATIENTS WITH PRURIGO NODOSUM | 2020 |
|
RU2822134C2 |
RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
Authors
Dates
2021-09-07—Published
2019-04-02—Filed